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Hepatitis C virus infects over 15 million patients from India and 2.86 million from Brazil.
Detection of anti-hepatitis C virus antibodies has limited sensitivity during acute phase: the
pre-seroconversion window period. Hepatitis C virus-RNA detection techniques are used
to overcome this shortfall, but are costly and unavailable widely in developing countries.
Estimation of hepatitis C virus core-antigen, a protein with highly conserved sequence, by
enzyme-immunoassays is an economic and simpler alternative to RNAdetection. This study
was conducted in Delhi, involving 300 acute and chronic liver disease patients, tested for
anti-hepatitis C virus 3rd-generation ELISA, hepatitis C virus core-antigen-ELISA andhepati-
tis C virus-RNA reverse transcription-polymerase chain reaction. Among the acute patients,
hepatitis C virus core-antigen assay could identify 13 out of 14 pre-seroconversion window
period cases and 6 out of 8 seroconverted cases, with a pre-seroconversion window period
sensitivity of 92.9% and speciﬁcity of 100%. In hepatitis C virus core-antigen-positive cases,
the viral load was in the range of 4900 to 1.46× 106 IU/mL, whereas in hepatitis C virus core-
antigen-negative cases, the range of viral load was 100–4500 IU/mL. The cost of the hepatitis
C virus core-antigen-ELISAwas estimated around 3–4 times lesser than the in-house reverse
transcription-polymerase chain reaction and 9–10 times lesser than the United States Foodand Drug Administration approved reverse transcription-polymerase chain reaction. With
a good sensitivity and speciﬁcity in the acute phase of infection, hepatitis C virus core-
antigen-ELISA can thus be a useful alternative in the developing nations.
estimated to be around 2.86 million. Chronic hepatitis C con-
© 2013 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDepatitis C virus (HCV), a single stranded enveloped RNA virus
elonging to the ﬂaviviridae family, is a globally signiﬁcant
athogen, infecting over 170 million individuals worldwide
ith about one million new cases being reported annually.1,2n India, approximately 15 million people are positive for
nti-HCV antibodies with reported prevalence of HCV approx-
mately 15–20% in chronic liver diseases (CLD) patients.3
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Este é um artigo Open Access sob a licençaPublished data from Brazil showed that around 1.5% of the
Brazilian population is anti-HCV positive,4 compounding it
to the current population, the HCV infection burden can belana Azad Medical College & Associated Lok Nayak Hospital, New
tributes to approximately 25–40% of all CLD and is the leading
cause of liver transplantation worldwide.2 Fewer than 15–25%
of cases of acute HCV infections result in the development
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of jaundice and therefore, the majority of cases are subclini-
cal. But the rate of chronicity following acute HCV infection is
pretty high (85%) compared to that of acute hepatitis B virus
(HBV) infection (1%).1,2 After infection with HCV, HCV RNA
becomes detectable in the serum within days to eight weeks.
It is usually present in the blood before the development of
jaundice, but the titer of the viral RNA may ﬂuctuate greatly,
and some patientsmay be intermittently negative for the HCV
RNA. The minimal interval following a suspected exposure
after which a persistently negative HCV polymerase chain
reaction (PCR) test rules out infection has not been deﬁnitely
established.1,2 Approximately one half of patients with symp-
tomatic acute infection have detectable antibodies to HCV
detected by ELISA when they ﬁrst present for care. However,
the development ofHCVantibodiesmaybedelayed in patients
whohave subclinical infection.Apositive anti-HCVELISAdoes
not distinguish between those who cleared the infection and
those who are chronically infected.2 The possibility of getting
false-positive or false-negative results is the drawback of this
method. The screening of HCV infection cannot rely solely on
anti-HCV ELISA in cases of acute hepatitis C, diagnosis of HCV
after occupational exposure, in babies born to HCV infected
mothers, in immunocompromised patients and individuals
on immunosuppressive therapy, thus warranting the use of
other supplemental assay.5 Thus, to overcome these shortfalls
of antibody screening for HCV, other supplementary tests are
essential,5 ofwhich themolecular biology based techniques to
detectHCVRNAarewidely used in clinical practice.6 Detection
of HCV RNA by nucleic acid ampliﬁcation techniques (NAT) is
expensive, time consuming, requires technical expertise and
dedicated laboratory area. These reasons restrict the avail-
ability or wide scale usage of HCV RNA detection in many
laboratories of developing countries.7,8
HCV core protein is a structural protein and its sequence is
highly conserved amongall HCVgenotypes andquasispecies.9
Detection of HCV core antigens (HCVcAg) for the diagnosis of
HCV infection, particularly in the pre-seroconversion window
period (PSWP), can be accomplished by several assays that are
available for research or commercial purposes, using serum,
plasma or whole blood samples.9,10 Ortho Clinical Diagnostic
is the most common provider worldwide, with its qualitative
screening HCVcAg ELISA and quantitative Ortho trak-c ELISA
(Ortho/J&J). There are at least two widely available commer-
cial assayswhich detect antigen and antibody simultaneously,
known as Monolisa Ultra Ag/Ab assay (Marnes-la-Coquette,
France) and Murex Ag/Ab combination assay (Abbott Murex,
Abbott Murex, Abbott Park, IL) aiming to narrow the window
period for positive diagnosis.11
Extensive review reports on the functioning ofMurexAg/Ab
combination assay, the Monolisa Ultra Ag/Ab assay and the
Ortho HCVcAg assay are available from The Health Protection
Agency (HPA), an independent UK organization, set up by the
UK government in 2003 for quality control of various drugs
and clinical assay techniques.12 The HPA reports have shown
that theOrthoHCVcAg assay is themost sensitive kit available
in terms of “timing analysis” on the commercial seroconver-
sion panels, when compared to nine other enzyme immuno
assays including the Murex Ag/Ab combination assay and the
Monolisa Ultra Ag/Ab assay. It detected seroconversion on an
average 3.5 days earlier than the Murex Ag/Ab combination13;17(3):369–374
assay, 5.5 days earlier than the Monolisa Ultra Ag/Ab assay
and 17.6 days earlier than the most sensitive antibody-only
EIA, i.e. Vitros ECi anti HCV assay (Ortho/J&J). However, the
HPA report had also stated that the antigen-only kits viz. Ortho
HCVcAg will usually detect positive specimens early in sero-
conversion but thenmay become negative due to suppression
of circulating antigen level by the antibody response. Anti-
gen degradation on long term storage of specimens were also
conjectured.12
Overall, antigen testing has shown good speciﬁcity but cur-
rently inadequate sensitivity in the setting of HCV therapeutic
monitoring or deﬁning sustained viral response (SVR). How-
ever, it has started to gain some popularity in some countries
(including resource poor countries) where it has been used for
early diagnosis of HCV.11,12
The present study was designed to assess whether the
HCVcAg test (Ortho/J&J) is a simple, cost-effective test as com-
pared to NAT and could be a good alternative to NAT for
the early diagnosis of HCV infection, particularly in the acute
phase of the illness and the PSWP, during which the infection
can be missed in a substantial number of cases, if anti-HCV
Ab testing is employed alone.
The study was conducted in the Department of Micro-
biology, Maulana Azad Medical College and associated Lok
Nayak Hospital, New Delhi during the period of May 2006
to July 2009. A total of 300 patients comprising 150 non-
A/non-E acute liver disease (ALD) cases and 150non-metabolic
CLD cases were included in the study. The diagnosis of
liver disease was based on previously reported clinical, bio-
chemical and histological criteria wherever feasible.2,13 ALD
cases included in the study were patients showing clini-
cal and/or biochemical jaundice (with an elevated bilirubin
level), with/without history of preceding prodromal symp-
toms, and increased alanine aminotransferase (ALT) levels
(at least 3 times more than the upper limit of normal value)
reported at least twice at an interval of one week without
any history of previous liver disease. Cases with detectable
anti-hepatitis A immunoglobulin M antibody (anti-HAV IgM)
and anti-hepatitis E antibody (anti-HEV Ab), previous his-
tory of jaundice, suspected and/or diagnosed surgical causes
and established metabolic and/or genetic liver diseases were
excluded. CLD patients were fresh ﬁrst contact cases pre-
senting to our hospital and were selected on the basis of
clinical and histopathological criteria described by Bianchi
et al.13 All CLD patients had continuous higher transaminases
level (at least thrice the normal value) for a period of more
than six months and histologic evidence of chronic hepatitis
on liver biopsy at the beginning of follow-up.2,13 Cases with
diagnosed metabolic or genetic liver diseases were excluded
from the study. Hepatitis B surface antigen (HBsAg) positive
cases were not excluded, due to sharing of common risk
factors for infection and wide report of co-infections. A sam-
ple with 5mL of blood was collected aseptically from each
study subject. Detailed clinical history and clinical examina-
tion, including risk factors, was undertaken according to a
predesigned protocol. Informed consent was obtained from
each patient, and the protocol for the study was approved
by the ethical committee and internal review board of the
institute. All serum samples were stored at −70 ◦C until
tested.
201
M
t
T
m
e
(
u
r
s
D
t
u
u
A
r
f
t
d
V
s
5
r
w
m
p
C
o
c
5
e
e
g
S
u
n
o
p
K
D
a
R
c
cbraz j infect d i s .
Anti-HCV antibody ELISA: a third generation ELISA Kit, HCV
icrolisa (J. Mitra & Co., New Delhi, India) was used to screen
he serum samples for the presence of anti-HCV antibodies.
he test was performed as per manufacturer’s instruction
anual.
Detection of HCVcAg: all samples were screened for the pres-
nce of HCVcAg by using the HCVcAg qualitative ELISA kit
OrthoDiagnostics/J&J, New Jersey, USA) according to theman-
facturer’s instructions.
Detection of HCV RNA by reverse transcription-polymerase chain
eaction (RT-PCR): viral RNA was extracted from all serum
amples using the High Pure Viral RNA Isolation Kit (Roche
iagnostics GmbH,Mannheim, Germany) as per themanufac-
urer’s instructions. The extracted RNA was stored at −70 ◦C
ntil tested.
Qualitative detection of HCV RNA: cDNA was transcribed
sing speciﬁc outer antisense primer (5′-ATGTACCCCATG
G/TA/GTCGGC-3′) from 5′ non-core region (NCR)–core
egion.14 Reverse transcription was carried out at 42 ◦C
or 1h followed by direct PCR in a reaction mixture con-
aining PCR buffer (10×), 2.5mmol/L MgCl2, 10mmol/L
NTPs, 0.75U Taq DNA polymerase (MBI Fermentas,
ilnius, Lithuania) and 20pmol of outer sense and anti-
ense primers (5′-ATGTACCCCATGAG/TA/GTCGGC-3′ and
′-ACTGCCTGATAGGGTGCTTGCGAG-3′) for 5′ NCR–core
egion, in a total reaction volume of 25L. Nested PCR
as performed in the reaction mixture containing PCR
aster mix (2×) and 20pmol inner sense and antisense
rimers (5′-AGGTCTCGTAGACCGTGCATCATG-3′ and 5′-
AC/TGTA/GAGGGTATCGATGAC-3′) in a total reaction volume
f 25L. The ﬁrst and second round of PCR comprised 35
ycles at the following conditions: 94 ◦C (denaturation),
5 ◦C (annealing), 72 ◦C (elongation), each for 60 s, with ﬁnal
xtension at 72 ◦C for 7min. The ampliﬁed PCR products were
lectrophoresed in ethidium bromide–stained 2% agarose
el and visualized in a Gel-Doc System (Alpha Innotech,
an Leandro, CA) for identifying desired 405bp fragment
sing 100bp digested molecular weight marker. Positive and
egative controls were also included.14
Quantitativemeasurement of HCV load:quantitative detection
f HCV RNA by real-time PCR was performed in all HCV RNA
ositive samples using the Roche Light Cycler TaqmanMaster
it on Roche Light Cycler 2.0 Real-Time PCR System (Roche
iagnostics GmbH,Mannheim, Germany). Each specimenwas
nalyzed in duplicate and themean value reported as the HCV
NA level in the serum. A known quantity of internal quality
ontrol serumwas included in eachpreparationof RT-PCR. The
ycle conditions of RT-PCR include 95 ◦C for 10min, followed
Table 1 – Results of different assays and their combinations in
Combinations of assay results in ALD cases
Anti HCV Ab + HCV RNA + HCVcAg +
Anti HCV Ab + HCV RNA + HCVcAg −
Anti HCV Ab − HCV RNA + HCVcAg +
Anti HCV Ab − HCV RNA + HCVcAg −
Anti HCV Ab +/− HCV RNA − HCVcAg +
ALD, acute liver disease; HCV, hepatitis C virus; HCVcAg, HCV core antigen3;17(3):369–374 371
by a further 40 cycles at 95 ◦C for 10 s, 58 ◦C for 15 s and 72 ◦C
for 10 s.14,16
Standard statistical methods and SPSS software version
18.0 were used to calculate sensitivity, speciﬁcity, positive and
negative predictive values. The agreement between HCVcAg
and HCV RNA for the detection of HCV infection was ana-
lyzed by kappa test. Two-sided p-value ≤0.05 was considered
statistically signiﬁcant.
Among the 150 non-A/non-E ALD cases, anti-HCV antibody
was detected in eight cases (5.33%). While 22 cases (14.67%)
were positive for HCV RNA by RT-PCR and 19 cases (12.66%)
were positive for HCV core antigen by HCVcAg assay. None
of these 22 HCV RNA positive cases had HBV co-infection. All
eight anti-HCV positive cases were positive for HCV RNA and
six were positive for HCVcAg. The 14 additional RT-PCR pos-
itive cases were presumably in the PSWP (14 out of total 22
PCR positive cases; 63.6%). As the HCV RNA assay is consid-
ered gold standard for the ALD cases, among the 142 anti-HCV
Ab negative cases (probable pre-seroconversion cases), true
HCV infections were present in 14. HCVcAg assay could suc-
cessfully detect 13 out of these 14 pre-seroconversion cases
(92.9%) (Table 1). The single case of ALD, which was unde-
tectable by HCVcAg but detected by RT-PCR had a serum HCV
RNA load of 1200 IU/mL. The two cases that were anti-HCV
Ab positive but HCVcAg negative, had serum HCV RNA levels
of 280 and 1350 IU/mL, respectively. The sensitivity of HCVcAg
assay was 92.86%when compared to HCV RNA in anti-HCV Ab
negative cases, and the speciﬁcity was 100%. The positive and
negative predictive values were 100% and 99.22% respectively.
When all the 150 ALD cases were considered, the sensitivity
of the HCVcAg assay comes down to 86.36%, probably reﬂect-
ing undetectable antigen levels in some ALD cases due to high
circulating antibody titers (see discussion below). However the
speciﬁcity and positive predictive value still remains high at
100%.
Out of the 150 cases of CLD without any diagnosed genetic
or metabolic causes, anti-HCV Ab was detected in 41 cases
(27.33%) by the third generation ELISA kit (J. Mitra & Co., New
Delhi, India) used in our study. HCV RNA was detected in 30
cases (20%) andHCVcAgwas detected in 28 cases (18.67%). The
11 cases tested positive for anti-HCV Ab that were negative
for HCV RNA, were retested for the presence of anti-HCV Ab
and were conﬁrmed to be positive. Conﬁrmation by recombi-
nant immunoblot assay (RIBA) or other methods for antibody
detection to detect false positivity of the third generation kit
was beyond the scope of this study. Among theCLD cases, HCV
RNA and HCVcAg both were positive in 27 cases; three cases
were positive for HCV RNA and negative for HCVcAg, and one
the cases of non-A/non-E acute liver disease cases.
No. of patients
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case was positive for HCVcAg, while negative for HCV RNA, on
repeated testing.
In this study,HCVviral load (serumHCVRNA level)was suc-
cessfully determined in all 52 HCV RNA positive patients. The
viral load ranged from 100 to 1.46× 106 IU/mL with a mean of
2.12× 105 IU/mL (std. deviation 3.27× 105, std. error 4.5× 104).
In 46 patients who were positive for HCVcAg, the viral load
was in the range of 4900–1.46× 106 IU/mL with a mean of
2.4× 105 IU/mL (std. deviation 3.38× 105, std. error 4.98× 105).
Whereas in the six samples which were negative for HCVcAg,
the viral load was in the range of 100–4500 IU/mL with a mean
of 1022 IU/mL (std. deviation 1711, std. error 698).
The cost per unit tested, were estimated for all the assays
and expressed in US dollars (USD), Brazilian Real (BRL) and
Indian Rupees (INR). The average cost per sample for HCV
Microlisa (J. Mitra & Co.) was 0.85–1 USD (1.7–2 BRL, 47–55
INR). The estimated cost per sample for the HCVcAg assay
(Ortho/J&J) was 4.84 USD (9.76 BRL, 267 INR). For the quali-
tative HCV RNA RT-PCR, it was 13.6 USD (27.16 BRL, 750 INR)
and for the in-house quantitative real time PCR, 17.77 USD
(35.5 BRL, 980 INR). The costs included only the cost of pack
of kits divided by the number of samples (excluding controls),
tested per pack. The cost incurred through manpower, estab-
lishment and depreciation of instruments were not included
for the sake of brevity.
HCV RNA detection by NAT remains gold standard for
the early diagnosis during PSWP and for conﬁrmation of
active HCV infection.5,6 To reduce the risk of HCV transmis-
sion during PSWP, testing of blood products for HCV RNA
by NAT is mandatory for European blood banks according to
the guidelines of the European Medicinal Evaluation Agency
since 1999.7 Detection of HCV RNA by PCR, or derivative
methods such as transcript-mediated ampliﬁcation (TMA),
permits the identiﬁcation of acutely infected donors before
their seroconversion for antibody to HCV, who would have
been missed by conventional serological tests. High costs,
time consumption, requirement of sophisticated equipment
and skilled manpower have turned it not to be frequently
used in the developing countries of Africa, Asia and Latin
America.15 Therefore, during past decades, researchers have
put enormous effort to develop HCVcAg ELISA, an otherwise
economic and easy to perform assay, as a potential alterna-
tive to NAT.6 Our study was intended to evaluate the clinical
utility of HCVcAg ELISA in early diagnosis of HCV infection. In
India the prevalence of hepatitis C has ranged from 10.8% to
as high as 48.5% depending upon the group of patient under
observation.15 In this study, the prevalence of HCV ranged
from 15.67% to 17.33% depending upon the test used for the
detection of infection, among the non-A/non-E ALD cases and
non-metabolic CLD cases. The exclusion of enterically trans-
mitted acute viral hepatitis (A and E) and the metabolic and
genetic causes of CLD might have increased the prevalence
rate in our study. Zhang et al. reported that HCVcAg ELISA
is able to identify most of the anti-HCV negative, HCV RNA
positive (PSWP) blood donation and reduced the length of
undetectable time span.15 In our present study, among the
cases of ALD, HCV RNA was detected in 22 cases. HCVcAg was
negative in only three cases, whereHCVRNAwas positive. Out
of these three cases, one was in the pre-seroconversion win-
dow, and two were positive for anti-HCV Ab. The single case13;17(3):369–374
of ALD in the pre-seroconversion window which had unde-
tectable HCVcAg but detectable RT-PCR had a serumHCV RNA
load of 1200 IU/mL, which was way below our estimated lower
limit of detection for the assay (4900 IU/mL). The remaining
two cases also had lower serum HCV RNA levels (280 and
1350 IU/mL respectively) in addition to the presence of high
titers of anti-HCV antibodies, which has the ability to neu-
tralize core antigens to below detectable range, as described
in earlier reports.12 Only eight cases of ALD were positive
for anti-HCV Ab among the 22 cases detected by HCV RNA,
leaving 14 cases in the pre-seroconversion window. HCVcAg
assay had otherwise successfully detected 13 out of those 14
HCV infected cases. Similar ﬁndings have been reported in
earlier studies which show the presence of HCV infection by
using HCVcAg ELISA during PSWP.9 In this study, the sensitiv-
ity, speciﬁcity, PPV, NPV of the HCVcAg assay to detect HCV
infection, compared to RT-PCR in cases of ALD were 86.36%,
100%, 100% and 97.71% respectively. Almost similar sensitivity
was reported by Netski et al. (87%) and Park et al. (90.2%).17,18
In our study, HCVcAg assay demonstrated a speciﬁcity of
100% in ALD cases, which is comparable to that reported
by Park et al. (100%) and Meidouge et al. (99.2%).10,18 In the
present study, viral load was in the range of 100–4500 IU/mL
in the six HCV RNA positive HCVcAg negative subjects. But,
ﬁve of the six samples were also positive for anti-HCV Ab,
thus leaving a room for chance of the antibodies neutral-
izing the circulating core antigens to below the detectable
level. This is in coherence to the ﬁndings of the HPA, UK,
where the HCVcAg assay (Ortho/J&J) was reported often to
be initially positive, but turn negative as time progresses,
even in cases with active HCV replication.12 The sample with
the lowest serum level of HCV RNA, which was tested pos-
itive for HCVcAg (4900 IU/mL) may be accepted as the lower
limit of range for analytical sensitivity for HCVcAg assay, from
our study. This ﬁnding is in agreement with other studies
which also recognize the to some extent low sensitivity of
HCVcAg assay for detection of HCV infection in low viral load
samples.6,17
We found 11 cases of CLD to be positive for anti-HCV Ab,
but negative either for HCV RNA or HCVcAg. These cases
had biochemical and histological features of CLD. The prob-
able explanations may be false positivity (which seems very
less likely, due to the usage of third generation ELISA kit),
cleared out infection or persistence of HCV in the liver, oth-
erwise undetected in the serum by HCV RNA PCR or HCVcAg
ELISA.
Currently, India has a population of 1210.2 million with
a total expenditure on health at purchasing power parity
(PPP) per capita of 122 International Dollars (Int. $), which
totals to a mere 4.2% of the country’s gross domestic prod-
uct (GDP), ranking 145 among the 194 enlisted countries in
the World Health Statistics 2011.19 The blood transfusion
system in India is a decentralized, fragmented, and hospital-
based system. There are approximately 1800 blood banks in
the country, out of which, 45% are governmental, 12% vol-
untary, 20% private, and 23% commercial. About 3.5million
20units are collected annually. At present, the country does not
have a uniformly accepted policy to screen the blood donors
for the possible carriage of HCV infection during the PSWP.
Though NAT based diagnosis of HCV infections are practiced
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n certain specialized private blood banks and laboratories,
he practice is not widespread due to the obvious reason of
ost.20 Brazil, with a population of 190.8 million, has some
400 hospitals, 620 blood collection sites, and the collection
nd processing of 4 million units of blood donated per year.20
pending some 8.4% of GDP, with an average expenditure of
75 Int. $ at PPP per capita on health, Brazil ranks 65th in the
HO list.19 NAT testing had been introduced only in seven
lood transfusion services (approximately 100,000units/year
otal) till 2003,20 and the country also does not seem to have
uniform policy to detect HCV infection during the pre-
eroconversion window on a routine basis among the blood
onors or ALD patients presenting to the public hospitals.
AT based screening for all blood donors has been introduced
n developed countries like United Kingdom and USA at the
eginning of this century. But the huge cost to beneﬁt ratio
ncurred by it on the public exchequer was highly criticized
y Simmond et al. in a highly cited commentary published
n The Lancet.7 More economic alternatives like the present
est used in our study, the Ortho HCVcAg assay was proposed
y Diment and Calmann,8 in response to the commentary,
iting its successful usage in public health sectors of many
uropean countries. It may have vital signiﬁcance for the lab-
ratories of developing countries, with a limited resources
etup due to its competing cost of 4.84 USD (9.76 BRL, 267
NR) per test, compared to 13.6 USD (27.16 BRL, 750 INR) for
he in-house qualitative RT-PCR based HCV RNA detection
ssay, 17.7 USD (35.5 BRL, 980 INR) for the in-house quanti-
ative real time PCR and 40.98 USD (81.89 BRL, 2261 INR) per
nit sample for the United States Food and Drug Administra-
ion (FDA) approved COBAS AmpliPrep/COBAS TaqMan HCV
ssay RT-PCR kit.
Thus, to summarize on the basis of extensive review of
iterature, we hypothesized that the HCVcAg test may be
imple and cost-effective as compared to NAT and that it
ould be a good alternative to NAT for the early diagnosis
f HCV infection, particularly in the acute phase of the ill-
ess and the PSWP, during which the infection can be missed
n a substantial number of cases, if anti-HCV Ab testing is
mployed alone. Our study lived up to our assumption to sug-
est that, the HCV core antigen based ELISA can be used for
creening patients presenting with signs and symptoms of
cute hepatitis, or in cases of screening for blood donors, in
ddition to antibody testing, as an alternative to the molec-
lar techniques, where the NAT based tests are not feasible
o apply in a mass scale due to economic or technical handi-
ap.
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